Is there a role for procalcitonin in differentiating uncomplicated and complicated diverticulitis in order to reduce antibiotic therapy? A prospective diagnostic cohort study

Jeger Victorab, Pop Roxanaa, Forudastan Farschadc, Barras Jean Pierre, Zuber Markusd, Piso Rein Janb

a Department of Internal Medicine, Kantonsspital Olten soH, Switzerland
b Department of Internal Medicine, University Hospital Zurich, Switzerland
c Department of Surgery, Kantonsspital Olten soH, Switzerland
d Department of Surgery, Bürgerspital Solothurn soH, Switzerland

Summary

AIMS OF THE STUDY: While studies show that antibiotic treatment for uncomplicated diverticulitis seems to have no benefit, most experts advocate antimicrobial therapy for complicated diverticulitis. However, even for uncomplicated diverticulitis, most clinicians are very reluctant to withhold antibiotics. Biomarkers could help to guide antibiotic therapy as this approach has been shown to be effective for acute respiratory infections. In this diagnostic cohort study we evaluated whether procalcitonin could be a biomarker to distinguish complicated from uncomplicated cases of diverticulitis.

METHODS: Complicated diverticulitis was defined as having abscess formation or perforation diagnosed by abdominal computed tomography (CT) scan. In all patients with suspected diverticulitis, procalcitonin values were measured at admission and on day 2. These values were blinded for clinicians, and treatment was carried out according to the physician’s judgement. Two groups (complicated vs uncomplicated diverticulitis) were defined. Patients who had received antibiotic treatment before admission were excluded. Difference in procalcitonin values was calculated for both groups using the Mann-Whitney test. Receiver operating characteristics (ROC) were calculated to determine cut-off values for procalcitonin according to the gold standard (abdominal CT scans).

RESULTS: 115 patients were included for analysis. 35 patients (30%) suffered from complicated diverticulitis. The median procalcitonin value for uncomplicated diverticulitis was significantly lower compared to complicated diverticulitis (median 0.05, interquartile range [IQR] 0.05–0.06 ng/l vs median 0.13, IQR 0.05–0.23 ng/l; p <0.0001). In the ROC analysis, the sensitivity and specificity were 81% and 91% when the highest procalcitonin value (days 1 and 2) was considered, with a cut-off value of 0.1 ng/l.

CONCLUSION: Procalcitonin was able to differentiate with a high sensitivity and specificity between complicated and uncomplicated cases of diverticulitis when combined with abdominal CT scans. As most clinicians still treat uncomplicated diverticulitis with antibiotics, procalcitonin could be an interesting parameter for guiding therapy and decreasing antibiotic usage. This should be further evaluated in randomised trials.

Key words: diverticulitis, complicated, uncomplicated, procalcitonin, antibiotics

Introduction

Although there is growing evidence to promote the avoidance of antibiotic therapy in uncomplicated diverticulitis [1, 2], physicians often continue to prescribe antibiotics in any case of diverticulitis. Availability of biomarkers would be useful to differentiate between complicated and uncomplicated diverticulitis and thereby guide antibiotic therapy. Complicated diverticulitis is usually defined as Hinchey 3b [3].

Procalcitonin has been identified as a biomarker in the diagnosis of bacterial infections in the setting of acute respiratory infections [4] and has been implemented in guidelines for antibiotic therapy in respective cases [4]. For abdominal infections, the data on reliable biomarkers are rather scarce. For appendicitis, procalcitonin failed to improve diagnosis and its sensitivity was even lower than C-reactive protein (CRP) [5]. However, procalcitonin was able to identify more complicated cases of appendicitis [5]. In sepsis in general, procalcitonin may be helpful early in the course of this heterogeneous disease to differentiate between bacterial infection and, e.g., post-operative inflammation [6]. However the role of procalcitonin in sepsis remains controversial and its trend (persistently high values vs faster clearing kinetics) rather than isolated values seem to have a higher clinical relevance [7].
Available reports on biomarkers in diverticulitis have been reviewed recently [8]. Mainly CRP has been evaluated in small cohort studies, which show only moderate sensitivity and specificity, and cannot be used as a single parameter. Recent data indicate a role for foetal calprotectin or matrix metalloproteinase in detecting diverticular disease, but it has not yet been clarified whether these parameters are useful for differentiation between complicated and uncomplicated courses of disease [8]. The role of procalcitonin has not been assessed so far.

The aim of the present prospective observational study was to evaluate if procalcitonin could differentiate between complicated and uncomplicated cases of diverticulitis compared to the gold-standard abdominal computed tomography (CT) scan. The aim was that results would guide further prospective trials for the more restrictive use of antibiotic therapy in cases of uncomplicated diverticulitis with appropriate procalcitonin cut-off levels.

Material and methods

We conducted a prospective diagnostic cohort study in two level-three emergency rooms and surgical wards in Switzerland (Kantonsspital Olten, Switzerland, and Bülgerspital Solothurn, Switzerland). The study was approved by the local ethics committee (north-western Switzerland, Licence no.: EKNZ 2015-135) in accordance with the Helsinki Declaration and the Swiss law for clinical studies. All patients gave written informed consent to a physician not involved in the study. Patients were enrolled into the study from September 2015 to December 2016.

Inclusion criteria were: suspected diverticulitis according to the treating physician (e.g., lower left abdominal pain, fever, referral from a general practitioner due to suspected diverticulitis), age ≥18 years, abdominal CT scan (requested by a physician responsible for patient care but independent of the study).

Exclusion criteria were severe immunodeficiency (ongoing chemotherapy; corticosteroid prescription >50 mg/d and >14 days; acute malignant haematological disease, human immunodeficiency virus [HIV] stage C3), inflammatory bowel disease.

Blood was drawn by nurses on admission to the emergency room and in the course of routine blood sampling the following day on the ward. Procalcitonin was determined in addition to routine blood parameters (blood count, electrolytes, creatinine, blood urea nitrogen, liver enzymes, C-reactive protein). At the time of admission, two pairs of blood cultures were collected. Physicians were blinded for procalcitonin values, as it is not the current standard of care to assess procalcitonin in cases of suspected abdominal infection.

CT scans of the abdomen were ordered according to the decision of the physician in charge and reviewed by specialist radiologists. CT scans of the abdomen were available 24 hours a day, 7 days a week and were reviewed on site or online (at night). Radiologists were blinded to the procalcitonin value. According to the radiology report, patients were scored as uncomplicated diverticulitis (Hinchey Score 0–1a) or complicated diverticulitis (with abscess formation, perforation, peritonitis; Hinchey Score Ib–IV).

Patient data, including clinical parameters as well as pre-hospital treatment, were obtained retrospectively from the patient chart.

Procalcitonin was measured with a one-step sandwich immunoassay with fluorescent detection (Vidas® BRAHMS PCT™). The lowest detection threshold was 0.05 ng/l.

Statistics

Patient data from complicated or uncomplicated diverticulitis were compared using the non-parametric Wilcoxon matched-pairs signed rank test for laboratory parameters at day 1 (admission) and day 2. Parameters between groups were compared using a Mann-Whitney test. Due to the dynamic kinetics of procalcitonin [9], the highest values of either day 1 (admission) or day 2 were compared. A p-value of 0.05 was considered significant. In case of multiple testing, p-values were corrected following the Bonferroni method. Receiver operating characteristics were calculated to determine cut-off values for procalcitonin according to the gold standard (abdominal CT scans). Prism 6 (GraphPad Software Inc, La Jolla, CA, USA) was used to calculate the statistics and draw the figures that appear in this paper. ROC curves of paired data were compared according to DeLong’s Method using R.

Results

From 167 recruited patients, 32 (19%) were excluded due to already established antibiotic therapy in the outpatient setting, 17 (10%) patients had no confirmation of diverticulitis and 3 (2%) had missing procalcitonin values at admission to the emergency room. Finally, 115 patients were included for analysis (fig. 1). 35 (30%) suffered from complicated diverticulitis. These patients had a longer duration of intravenous antibiotic treatment as well as a longer duration of hospitalisation (table 1). Even in uncomplicated cases, almost all patients received antibiotic therapy (details of antibiotic therapy are shown in table 1). Only one out of 19 blood cultures drawn on admission to the emergency room from complicated cases revealed a positive culture result (Escherichia coli and Streptococcus anginosus).

Procalcitonin at admission (day 1) was significantly higher in patients with complicated diverticulitis compared to patients with uncomplicated diverticulitis (median 0.13, interquartile range [IQR] 0.05–0.23 ng/l vs median 0.05, IQR 0.05–0.06; p <0.0001). If the highest procalcitonin values of day 1 or day 2 were compared between the two groups, a significant difference was observed (median 0.21, IQR 0.12–0.75 ng/l vs median 0.05, IQR 0.05–0.07; p <0.0001). CRP and leucocyte count of complicated and uncomplicated diverticulitis were not significantly different at time of admission (table 2). Compared to the gold standard (abdominal CT scan), ROC curves of procalcitonin show moderate sensitivity (80%) and high specificity (91%) at a cut-off point of 0.1 ng/l when the highest value was considered (measured at admission or day 2) (area under the curve [AUC] 0.867; confidence interval [CI] 0.791–0.942). The procalcitonin (AUC 0.742; CI 0.633–0.852) as well as the CRP value (AUC 0.635; CI 0.509–0.761) at admission showed only moderate sensitivity and specificity (fig. 2). The ROC curve and AUC for highest procalcitonin was not signifi-
cantly different compared to the AUC of highest CRP (p = 0.144; AUC for highest CRP 0.782; CI 0.682–0.881).

**Discussion**

Diverticulitis is a frequent diagnosis, with about 75 hospital admissions per 100,000 persons per year, and has a low mortality rate of less than 1% [10]. The true incidence may be even higher, as many cases are treated outside hospitals by family physicians.

Although it is generally believed that diverticulitis results from microperforation of the diverticulum, some authors have hypothesised that diverticulitis is a form of inflammatory bowel disease [11]. The indication for antibiotic treatment has therefore been a challenge for many years [12]. Specific biomarkers for abdominal infections are missing. Mainly CRP and calprotectin have been assessed for diverticulitis but with only moderate specificity and sensitivity [8]. No reports on procalcitonin and diverticulitis are currently available. However, procalcitonin has been evaluated in cases of appendicitis where it showed a strong diagnostic value if abscess formation or perforation was present [13]. However, procalcitonin was not useful as a single parameter to diagnose appendicitis. In a recent published study, the authors studied the role of procalcitonin as a marker to guide antibiotic therapy in cases of peritonitis after surgery [14]. Subgroup analysis revealed a trend for shorter duration of therapy in the procalcitonin group, but the study was underpowered due to small sample size. It is therefore not clear whether procalcitonin is able to guide antibiotic therapy in the case of bacterial peritonitis following surgery.

The use of procalcitonin as a biomarker has been shown to decrease antibiotic consumption in respiratory infections [9]. We believe that treatment and clinical course of diverticulitis have some similarities to respiratory infections.

Even if procalcitonin did not show superiority compared to other biomarkers in abdominal infections [5], it could have its place in the case of diverticulitis. Similar to respiratory infections, most cases of diverticulitis are of non-bacterial origin [15], but in complicated diverticulitis, which often leads to peritonitis, patients may benefit from antibiotic treatment. Similar to non-bacterial respiratory infections,

---

**Table 1:** Demographics and characterisation of antibiotic (AB) treatment of complicated and uncomplicated cases of diverticulitis.

<table>
<thead>
<tr>
<th>Complicated</th>
<th>Uncomplicated</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cases (n)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>35</td>
<td>80</td>
<td>0.962</td>
</tr>
<tr>
<td>Age (years, median, range)</td>
<td>62 (31–67)</td>
<td>61 (33–90)</td>
</tr>
<tr>
<td>Gender (mvf)</td>
<td>16/19</td>
<td>36/44</td>
</tr>
<tr>
<td>Hospitalisation (days, median, range)</td>
<td>7 (3–45)</td>
<td>4 (1–17)</td>
</tr>
<tr>
<td>Positive blood culture</td>
<td>(1/19)</td>
<td>(0/18)</td>
</tr>
<tr>
<td>Antibiotic therapy (n)</td>
<td>35</td>
<td>78</td>
</tr>
<tr>
<td>Intravenous AB therapy</td>
<td>35</td>
<td>68</td>
</tr>
<tr>
<td>Days of AB therapy intravenous (median, range)</td>
<td>6 (3–25)</td>
<td>4 (0–14)</td>
</tr>
</tbody>
</table>

**Type**

<table>
<thead>
<tr>
<th>Medication</th>
<th>Complicated</th>
<th>Uncomplicated</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cotrimoxazole</td>
<td>16</td>
<td>41</td>
<td>0.51</td>
</tr>
<tr>
<td>Ceftriaxone/metronidazole</td>
<td>14</td>
<td>24</td>
<td>0.30</td>
</tr>
<tr>
<td>Ciprofloxacin/metronidazole</td>
<td>3</td>
<td>2</td>
<td>0.03</td>
</tr>
<tr>
<td>Amoxicillin-clavulanic acid</td>
<td>0</td>
<td>1</td>
<td>0.01</td>
</tr>
<tr>
<td>Meropenem</td>
<td>1</td>
<td>0</td>
<td>0.00</td>
</tr>
<tr>
<td>Cefepime/metronidazole</td>
<td>1</td>
<td>0</td>
<td>0.00</td>
</tr>
<tr>
<td>Days of oral AB therapy (median, range)</td>
<td>7 (0–15)</td>
<td>7 (3–13)</td>
<td></td>
</tr>
</tbody>
</table>

**Type**

<table>
<thead>
<tr>
<th>Medication</th>
<th>Complicated</th>
<th>Uncomplicated</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amoxicillin-clavulanic acid</td>
<td>16</td>
<td>55</td>
<td>0.69</td>
</tr>
<tr>
<td>Ciprofloxacin/metronidazole</td>
<td>11</td>
<td>20</td>
<td>0.25</td>
</tr>
<tr>
<td>Amoxicillin</td>
<td>1</td>
<td>0</td>
<td>0.00</td>
</tr>
<tr>
<td>Amoxicillin-clavulanic acid/metronidazole</td>
<td>0</td>
<td>3</td>
<td>0.4</td>
</tr>
<tr>
<td>Cefuroxime/metronidazole</td>
<td>1</td>
<td>0</td>
<td>0.00</td>
</tr>
<tr>
<td>Levofloxacin/metronidazole</td>
<td>1</td>
<td>0</td>
<td>0.00</td>
</tr>
<tr>
<td>Cotrimoxazole</td>
<td>1</td>
<td>0</td>
<td>0.00</td>
</tr>
<tr>
<td>None</td>
<td>4</td>
<td>0</td>
<td>0.00</td>
</tr>
</tbody>
</table>

**Table 2:** Procalcitonin, C-reactive protein and leucocyte count on admission (day 1) and day 2.

<table>
<thead>
<tr>
<th>Procalcitonin (ng/l)</th>
<th>Median</th>
<th>IQR</th>
<th>Median</th>
<th>IQR</th>
<th>Median</th>
<th>IQR</th>
<th>Uncomplicated; administration vs day 2</th>
<th>Complicated; administration vs day 2</th>
<th>Admission; uncomplicated vs complicated</th>
<th>Day 2; uncomplicated vs complicated</th>
</tr>
</thead>
<tbody>
<tr>
<td>PCT</td>
<td>0.05</td>
<td>0.05–0.06</td>
<td>0.05</td>
<td>0.05–0.06</td>
<td>0.13</td>
<td>0.05–0.23</td>
<td>0.16</td>
<td>0.12–0.63</td>
<td>0.712</td>
<td>0.022</td>
</tr>
<tr>
<td>CRP</td>
<td>79</td>
<td>45–113</td>
<td>94</td>
<td>55–121</td>
<td>123</td>
<td>53–201</td>
<td>149</td>
<td>115–239</td>
<td>0.05</td>
<td>0.004</td>
</tr>
<tr>
<td>leucocytes (G/l)</td>
<td>11.4</td>
<td>9.1–14.2</td>
<td>8.4</td>
<td>6.5–11.0</td>
<td>12.6</td>
<td>10.4–14.9</td>
<td>10.4</td>
<td>8.3–13.3</td>
<td>&lt;0.0001</td>
<td>0.004</td>
</tr>
</tbody>
</table>

CPT = C-reactive protein; PCT = procalcitonin. Data are shown as median and interquartile range (IQR). Differences between groups (e.g., complicated vs uncomplicated) were compared using the unpaired Mann-Whitney test. Differences between admission (day 1) and day 2 within each group of either complicated or uncomplicated diverticulitis were compared using the paired Wilcoxon matched-pairs test. According to the Bonferroni method, a p-value of 0.0125 was considered significant after four multiple tests.
most clinicians might be very reluctant to omit antibi-

tic treatment for uncomplicated diverticulitis to avoid and

prevent complications due to a possible bacterial infection.

This was the case in our present study, where most patients

with uncomplicated diverticulitis were treated with antibi-

tics.

Our results indicate that procalcitonin may be useful to

differentiate uncomplicated from complicated diverticuli-

tis when compared to the gold standard of abdominal CT

scans. Procalcitonin values had a tendency to higher sensi-

tivity and specificity compared to CRP in discerning com-

plicated from uncomplicated diverticulitis, but their AUC

were not significantly different, probably due to the small

sample size. In 9% of the patients with complicated diver-

ticulitis, procalcitonin values were below 0.1 ng/l, which

therefore makes this method of analysis unsuitable as a re-

placement for CT scans. In addition, the procalcitonin val-

ue on admission had only moderate sensitivity and specific-

ity, so a follow-up procalcitonin value on day 2 seems to

be necessary. This may be due to the dynamic kinetics of

procalcitonin [9] and the delay between onset of infec-

tion and measurement of procalcitonin. In summary, we do

not conclude that measurement of procalcitonin could re-

place CT scans or that it should be used as a single parame-

ter, but in the case of uncomplicated diverticulitis, it could

have the potential to rule out antibiotic treatment. We hy-

pothesise that in the patient population of the present study,

procalcitonin-guided treatment would have decreased anti-

biotic treatment by 80%. This is a similar percentage com-

pared to studies using procalcitonin in respiratory in-

fections, where a marked reduction of antibiotic consump-

tion was observed [9]. If laboratory tests support clinicians

in omitting antibiotic treatment for uncomplicated diverticuli-

tis, its use would be justified in addition to radiological

imaging.

We are aware that our study is rather small. The aim was
to gain indications of whether procalcitonin is able to dif-

ferentiate between complicated and uncomplicated diver-

ticulitis. Our results show that procalcitonin in addition to

CT could support clinicians’ decisions on whether antibi-

otic treatment is necessary.

Further studies need to be done to answer this question in

order to reduce antibiotic treatment in uncomplicated di-

verticulitis. These studies should be performed as multi-

centre studies using larger sample sizes to obtain strong ev-

Figure 1: Included and excluded patients. All recruited patients
gave written informed consent. Patients were excluded for analysis
if the CT scan did not confirm suspected clinical diagnosis of diver-
ticulitis, if procalcitonin was not determined at admission, or if pa-
tients had already received antibiotic treatment in the outpatient
setting before admission to the emergency room.

Figure 2: ROC (receiver operating characteristic) curve of procalcitonin against the gold standard of abdominal CT scan. The highest procalci-
tonin serum concentration of day 1 (admission) or day 2 showed a sensitivity of 80% and a specificity of 91%. AUC is indicated with 95% con-

fidence interval in brackets.
idence for the use of procalcitonin in guidance of antibiotic therapy in diverticulitis.

Disclosure statement
No financial support and no other potential conflict of interest relevant to this article was reported.

References